Study of pembrolizumab combined with ataluren in Patients with metastatic pMMR and dMMR colorectal cancer adenocarcinomas or metastatic dMMR endometrial carcinoma: the ATAPEMBRO study. - ATAPEMBRO

Amsterdam University Medical Centers location AMC0 个研究点目标入组 47 人开始时间: 2019年2月18日最近更新: 2019年2月28日

适应症

试验速览

暂无简介。

•- Metastatic or irresectable locally advanced mismatch repair proficient or deficient colorectal carcinoma or mismatch repair deficient endometrial carcinoma
•- Have received or refused at least one chemotherapy treatment for metastatic disease
•- Life expectancy greater than 3 months
•- Normal organ and marrow function (as defined in protocol)
•- Be willing and able to provide metastasis tissue pre and post treatment by core or excissional biopsy.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 17
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 30

•- (Partner is) currently pregnant or breastfeeding or is planning to become pregnant or nurture a child during the duration of the trial and a designated period thereafter.
•- Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti OX-40, anti-CD40 or anti-CTLA-4.
•- Active central nervous system metastsasis or carcinomateus meningitis
•- (History of) auto-immune disease
•- Immunodeficiency or use of immunosuppressing drugs.
•- Active infection
•- Uncontrolled intercurrent disease (for example hearth failure)
•- (History of) active Tuberculosis
•- HIV, Hep A, Hep B.

发起方

Amsterdam University Medical Centers location AMC